Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
BPC-157 Arginate (Stable Form)
BPC-157 Arginine Salt, BPC-157-Arg
A stabilized oral formulation of the BPC-157 pentadecapeptide sequence designed for gastrointestinal applications. Unlike standard BPC-157 which is typically injected, this formulation uses stabilization techniques to survive gastric acid degradation. Primarily studied for gut healing, ulcer protection, and inflammatory bowel conditions.
The arginine salt form of BPC-157, developed to improve stability and shelf life compared to the standard acetate salt. BPC-157 arginate maintains the same gastric pentadecapeptide sequence but uses arginine as the counter-ion, which provides better stability at room temperature and in solution. This form is increasingly preferred by compounding pharmacies and researchers.
Same core mechanism as BPC-157 — upregulates growth factor expression (VEGF, EGF), promotes angiogenesis, and modulates the nitric oxide system. The oral formulation targets the GI tract directly, providing local healing effects on the gastric and intestinal mucosa before systemic absorption.
Same mechanism as standard BPC-157 — upregulates growth factor expression (VEGF, FGF, EGF), promotes angiogenesis, modulates nitric oxide pathways, and interacts with the dopaminergic system. The arginine counter-ion does not change the peptide's pharmacological activity but improves chemical stability, particularly in aqueous solution.
- Gut healing and repair
- Gastric ulcer protection
- Inflammatory bowel support
- Leaky gut syndrome (investigational)
- NSAID-induced GI damage protection
- Gut healing and GI repair
- Tendon and ligament recovery
- Muscle injury repair
- Neuroprotection
- Stable alternative to BPC-157 acetate
- Limited human clinical data
- GI discomfort possible
- Uncertain bioavailability compared to injectable
- Quality varies significantly between suppliers
- Not FDA-approved for any indication
- Same risk profile as standard BPC-157
- No FDA-approved human trials
- Theoretical concerns about growth factor upregulation
- Quality varies between sources
Shares regulatory status with BPC-157. Removed from Category 2 on April 22, 2026. Awaiting PCAC review at the July 23, 2026 meeting. The oral formulation is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: 2026-07-23
Same regulatory status as BPC-157. Removed from Category 2 on April 15, 2026. Scheduled for PCAC review on July 23, 2026 (Day 1). The arginate form is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.